Tadalafil is a clinically approved phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction and pulmonary arterial hypertension. It contains two chiral carbons, and the marketed isomer is the , isomer with a methyl substituent on the terminal nitrogen of the piperazinedione ring. In this report, tadalafil analogues with an extended hydrophilic side chain on the piperazine nitrogen were designed to interact with particular hydrophilic residues in the binding pocket. This leads to analogues with moderate inhibitory activity on phosphodiesterase-5, even for isomers in which chiral carbons are of the configuration.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064235PMC
http://dx.doi.org/10.3390/scipharm84030428DOI Listing

Publication Analysis

Top Keywords

hydrophilic side
8
side chain
8
chiral carbons
8
structure-based design
4
design novel
4
novel tetrahydro-beta-carboline
4
tetrahydro-beta-carboline derivatives
4
derivatives hydrophilic
4
chain potential
4
potential phosphodiesterase
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!